drugset / Trial / NCT06487572
A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants
RandomizedParallel-groupOpen-labelBasic science
Summary
The objective of this study is to compare pharmacokinetic exposures following intravenous and subcutaneous administration of Risankizumab.
Timeline
- Start
- 2024-07-23
- Primary completion
- 2025-02-07
- Completion
- 2025-02-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Risankizumab | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.